FBR & Co. Sees Quick Resolution to Aduro Biotech's (ADRO) Partial Clinical Hold; Trims PT to $20

October 24, 2016 3:10 PM EDT
Get Alerts ADRO Hot Sheet
Price: $11.70 +1.74%

Rating Summary:
    5 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade ADRO Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

FBR & Co. trims its price target on Outperform-rated Aduro Biotech (Nasdaq: ADRO) from $22 to $20 after the company announced that it received notice from the U.S. Food and Drug Administration (FDA) that trials with investigational agents based on its LADD (Listeria-based immunotherapy construct) platform have been placed on partial clinical hold to pause new patient enrollment.

The firm commented today: After speaking with management after the call, we feel confident that the clinical hold will be resolved in a relatively short period of time. The program is currently in clinical development for six indications, including pancreatic, lung, prostate, and ovarian cancers, as well as mesothelioma and glioblastoma. On the call, the company informed us that while it will implement modifications to all LADD program protocols, the ongoing STING and B-select programs will not be affected. We recognize that this event likely adds more risk to the LADD platform; however, we see this as a temporary and manageable setback.

For an analyst ratings summary and ratings history on Aduro Biotech click here. For more ratings news on Aduro Biotech click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Add Your Comment